Johnson & Johnson reported positive Phase 3 FUZION study results for TREMFYA (guselkumab) at Digestive Disease Week 2026.
The trial evaluated the drug in adults with active perianal fistulizing Crohn's disease.
TREMFYA is the first and only IL-23 inhibitor to demonstrate efficacy for this condition in a clinical trial.
Patients treated with TREMFYA achieved significantly higher combined fistula remission rates at 24 weeks compared to placebo.
This study marks the first randomized controlled trial in 20 years to show efficacy for an approved inflammatory bowel disease therapy in this patient population.